APOE and Alzheimer disease: Furthermore, our findings, aligned with the recent study7, indicate that APOE4 homozygosity uniquely alters the plasma metabolome and its associations with ADRD risk, underscoring the necessity of distinguishing homozygotes from heterozygotes in investigations of APOE4’s role in AD pathology.